MedinCell S.A.

Paris Stock Exchange MEDCL.PA

MedinCell S.A. Return on Assets (ROA) for the year ending March 31, 2024: -67.77%

MedinCell S.A. Return on Assets (ROA) is -67.77% for the year ending March 31, 2024, a 37.89% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

MedinCell S.A. Return on Assets (ROA) for the year ending March 31, 2023 was -109.10%, a -94.86% change year over year.
MedinCell S.A. Return on Assets (ROA) for the year ending March 31, 2022 was -55.99%, a -87.58% change year over year.
MedinCell S.A. Return on Assets (ROA) for the year ending March 31, 2021 was -29.85%, a 65.92% change year over year.
MedinCell S.A. Return on Assets (ROA) for the year ending March 31, 2020 was -87.58%, a -68.96% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Paris Stock Exchange: MEDCL.PA

MedinCell S.A.

CEO	Mr. Christophe Douat
IPO Date	Oct. 8, 2018
Location	France
Headquarters	3 rue des Frères Lumière
Employees	134
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.

Key trends

Past 5 years